Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Single-cell RNA sequencing has established itself as one of the most important technologies for studying the transcriptome of ... Single Cell with the newest 10X Genomics assay on two different ...

Parse has now invalidated all claims that 10x Genomics asserts against Parse products, further reinforcing Parse’s ability to drive ongoing innovation in the single cell space. In defense of ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

2025 revenue guidance suggests 0-3% growth, with a focus on biopharma and single-cell projects. 10X Genomics experienced a challenging Q4 2024, with revenue declining by 10% year-over-year to $165 ...